Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance

Table 3

Biochemical indicator level, CIMT, BMI, and blood pressure of two groups between pre- and posttreatment (mean ± SD).

	Control group		Acarbose group
	Pretreatment	Posttreatment	Pretreatment	Posttreatment
FPG, mmol/L	5.84 ± 0.33	5.95 ± 0.54	5.92 ± 0.42	5.78 ± 0.69
2 hPG, mmol/L	8.76 ± 0.49	9.46 ± 1.22	8.98 ± 0.54	7.64 ± 1.08^#,▲
HbA1c, %	6.28 ± 0.23	6.36 ± 0.51	6.30 ± 0.28	5.92 ± 0.24^#,▲
Systolic, mmHg	148.54 ± 8.63	140.27 ± 6.25	150.16 ± 10.38	138.82 ± 7.14^▲
Diastolic, mmHg	93.26 ± 5.34	88.51 ± 4.62	94.13 ± 7.18	87.73 ± 5.18^▲
TC, mmol/L	6.24 ± 1.03	5.06 ± 0.96	6.38 ± 1.35	5.03 ± 0.87^▲
TG, mmol/L	2.36 ± 0.58	1.74 ± 0.52	2.45 ± 0.62	1.65 ± 0.38^▲
LDL-C, mmol/L	3.07 ± 0.66	2.56 ± 0.52	3.18 ± 0.75	2.58 ± 0.58^▲
BMI, kg/m^2	25.86 ± 2.45	25.64 ± 2.75	26.02 ± 3.47	24.65 ± 3.13^▲
CIMT, mm	1.23 ± 0.46	1.49 ± 0.54	1.24 ± 0.52	1.28 ± 0.41^#
ΔCIMT, mm	0.22 ± 0.07		0.05 ± 0.02^#

, versus the control group before treatment; , versus the control group after treatment; , versus the acarbose group before treatment.